Cargando…
NS5ABP37 inhibits liver cancer by impeding lipogenesis and cholesterogenesis
The molecular mechanism underlying non‐alcoholic fatty liver disease progression to hepatocellular carcinoma (HCC) remains unknown. In this study, immunohistochemistry staining results showed that NS5ABP37 protein, which is in a state of lower expression in tumor tissues, decreased with increasing d...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5276832/ https://www.ncbi.nlm.nih.gov/pubmed/27862769 http://dx.doi.org/10.1111/cas.13117 |
_version_ | 1782502349142491136 |
---|---|
author | Feng, Shenghu Han, Ming Zhou, Li Wang, Qi Li, Zhongshu Li, Yaru Lu, Hongping Liu, Ting Ma, Yanhua Liu, Shunai Cheng, Jun |
author_facet | Feng, Shenghu Han, Ming Zhou, Li Wang, Qi Li, Zhongshu Li, Yaru Lu, Hongping Liu, Ting Ma, Yanhua Liu, Shunai Cheng, Jun |
author_sort | Feng, Shenghu |
collection | PubMed |
description | The molecular mechanism underlying non‐alcoholic fatty liver disease progression to hepatocellular carcinoma (HCC) remains unknown. In this study, immunohistochemistry staining results showed that NS5ABP37 protein, which is in a state of lower expression in tumor tissues, decreased with increasing degree of HCC malignancy. Two cell models, HepG2 and L02, were used to analyze the mechanism between NS5ABP37 and HCC. In agreement, NS5ABP37 protein overexpression significantly suppressed cell proliferation, caused G(1)/S cell cycle arrest, and induced apoptosis by increasing caspase‐3/7 activity and cleaved caspase‐3 levels. In addition, NS5ABP37 overexpression resulted in decreased intracellular triglyceride and total cholesterol contents, with level reduction in sterol regulatory element‐binding proteins (SREBPs) and downstream effectors. Furthermore, NS5ABP37 overexpression decreased SREBP1c and SREBP2 levels by reducing their respective promoters. Finally, reactive oxygen species levels and endoplasmic reticulum stress were both induced by NS5ABP37 overexpression. These findings together indicate that NS5ABP37 inhibits cancer cell proliferation and promotes apoptosis, by altering SREBP‐dependent lipogenesis and cholesterogenesis in HepG2 and L02 cells and inducing oxidative stress and endoplasmic reticulum stress. |
format | Online Article Text |
id | pubmed-5276832 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-52768322017-02-01 NS5ABP37 inhibits liver cancer by impeding lipogenesis and cholesterogenesis Feng, Shenghu Han, Ming Zhou, Li Wang, Qi Li, Zhongshu Li, Yaru Lu, Hongping Liu, Ting Ma, Yanhua Liu, Shunai Cheng, Jun Cancer Sci Original Articles The molecular mechanism underlying non‐alcoholic fatty liver disease progression to hepatocellular carcinoma (HCC) remains unknown. In this study, immunohistochemistry staining results showed that NS5ABP37 protein, which is in a state of lower expression in tumor tissues, decreased with increasing degree of HCC malignancy. Two cell models, HepG2 and L02, were used to analyze the mechanism between NS5ABP37 and HCC. In agreement, NS5ABP37 protein overexpression significantly suppressed cell proliferation, caused G(1)/S cell cycle arrest, and induced apoptosis by increasing caspase‐3/7 activity and cleaved caspase‐3 levels. In addition, NS5ABP37 overexpression resulted in decreased intracellular triglyceride and total cholesterol contents, with level reduction in sterol regulatory element‐binding proteins (SREBPs) and downstream effectors. Furthermore, NS5ABP37 overexpression decreased SREBP1c and SREBP2 levels by reducing their respective promoters. Finally, reactive oxygen species levels and endoplasmic reticulum stress were both induced by NS5ABP37 overexpression. These findings together indicate that NS5ABP37 inhibits cancer cell proliferation and promotes apoptosis, by altering SREBP‐dependent lipogenesis and cholesterogenesis in HepG2 and L02 cells and inducing oxidative stress and endoplasmic reticulum stress. John Wiley and Sons Inc. 2017-01-29 2017-01 /pmc/articles/PMC5276832/ /pubmed/27862769 http://dx.doi.org/10.1111/cas.13117 Text en © 2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Feng, Shenghu Han, Ming Zhou, Li Wang, Qi Li, Zhongshu Li, Yaru Lu, Hongping Liu, Ting Ma, Yanhua Liu, Shunai Cheng, Jun NS5ABP37 inhibits liver cancer by impeding lipogenesis and cholesterogenesis |
title |
NS5ABP37 inhibits liver cancer by impeding lipogenesis and cholesterogenesis |
title_full |
NS5ABP37 inhibits liver cancer by impeding lipogenesis and cholesterogenesis |
title_fullStr |
NS5ABP37 inhibits liver cancer by impeding lipogenesis and cholesterogenesis |
title_full_unstemmed |
NS5ABP37 inhibits liver cancer by impeding lipogenesis and cholesterogenesis |
title_short |
NS5ABP37 inhibits liver cancer by impeding lipogenesis and cholesterogenesis |
title_sort | ns5abp37 inhibits liver cancer by impeding lipogenesis and cholesterogenesis |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5276832/ https://www.ncbi.nlm.nih.gov/pubmed/27862769 http://dx.doi.org/10.1111/cas.13117 |
work_keys_str_mv | AT fengshenghu ns5abp37inhibitslivercancerbyimpedinglipogenesisandcholesterogenesis AT hanming ns5abp37inhibitslivercancerbyimpedinglipogenesisandcholesterogenesis AT zhouli ns5abp37inhibitslivercancerbyimpedinglipogenesisandcholesterogenesis AT wangqi ns5abp37inhibitslivercancerbyimpedinglipogenesisandcholesterogenesis AT lizhongshu ns5abp37inhibitslivercancerbyimpedinglipogenesisandcholesterogenesis AT liyaru ns5abp37inhibitslivercancerbyimpedinglipogenesisandcholesterogenesis AT luhongping ns5abp37inhibitslivercancerbyimpedinglipogenesisandcholesterogenesis AT liuting ns5abp37inhibitslivercancerbyimpedinglipogenesisandcholesterogenesis AT mayanhua ns5abp37inhibitslivercancerbyimpedinglipogenesisandcholesterogenesis AT liushunai ns5abp37inhibitslivercancerbyimpedinglipogenesisandcholesterogenesis AT chengjun ns5abp37inhibitslivercancerbyimpedinglipogenesisandcholesterogenesis |